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 The 6H-oxazolo[3,2-f]pyrimidine-5,7-dione motive could serve as a convenient scaffold for the design of bioactive molecules with activity against various therapeutic targets (Fig. 1). Oxazolopyrimidine 1 and structurally related compounds were designed as potential selective inhibitors of collagenase 3 (matrix metalloproteinase 13),1 whereas derivative 2 exhibited potent activity against human gonadotropin-releasing hormone (hGnRH) receptor with binding affinity in the low nanomolar range (4.5 nM).2 6H-Oxazolo[3,2-f]pyrimidine-5,7-diones can be readily synthesized as racemates by the reaction of 2-alkenyloxazolines with isocyanates3 or 2-alkyloxazolines with α,α-disubstituted diacid chlorides.4-6 Such compounds have also been obtained in a cyclisation-hydrogen halide elimination reaction from 5-halogeno-1-(3-hydroxypropyl)uracils after treatment with base.7,8 

Fig. 1 Examples of biologically active 6H-oxazolo[3,2-f]pyrimidine-5,7-dione derivatives 1-2 and synthetic targets 3 in the current project 

As a part of our on-going research on the design and synthesis of new, medicinally relevant heterocyclic derivatives such as  peptidomimetics,9 benzodiazepine10 and nucleoside analogues,11-13 we developed the synthesis of optically pure derivatives of (S)-3-hydroxy-2,3-dihydro-6H-oxazolo[3,2-f]pyrimidine-5,7-dione 3a-k (Schemes 1-3), which could serve as a new structural scaffold for drug design. Our work on the synthesis of novel fused pyrimidine ring systems was partially inspired by results of Chen and colleagues14 who reported the synthesis of purine N3,5'-cyclo-2',3'-seconucleosides from N3,5'-cyclonucleosides as possible HIV non-nucleoside reverse transcriptase inhibitors (NNRIs). Although the described compounds did not exhibit any antiretroviral activity, the reported results revealed the possibility of application of cyclonucleosides as valuable substrates for the synthesis of novel fused heterocyclic systems. In this work we utilised 6,5’-O-anhydrouridine nucleosides synthesise of 2’,3’-seconucleoside derivatives using the Chen protocol14 and investigated the cytotoxic effect of the synthesised products.

2. Results and Discussion

In initial experiments, we used 6,5’-O-anhydrouridine derivatives 4a-c, the synthesis of which was recently published by one of us (Scheme 1).11 Thus, nucleosides 4a-c were dispersed in water and treated with sodium periodate which resulted in substrate dissolution after several minutes. When no more starting material was detected by LRMS and TLC (typically 15 min), sodium borohydride was added and the reaction mixture left at room temperature for 20 h. In most cases the sole product was isolated from the reaction mixture by column chromatography. Analysis of the NMR spectra and single X-ray structure of one of the analogue 3d (Scheme 2) revealed that the obtained products possessed the structure of 6H-oxazolo[3,2-f]pyrimidine-5,7-dione 3 instead of the expected 2,3-dihydropyrimido[6,1-b][1,5,3]dioxazepine-7,9(5H,8H)-dione 5 and that rearrangement/ring contraction of the dioxazepine ring in 4 had occurred under conditions described by Chen. 


Scheme 1. Reagents and conditions: (a) NaIO4, H2O, rt, 15 min; (b) NaBH4, H2O, rt, 20 h. (yields added to the scheme)
After the unexpected transformation of 6,5’-O-anhydrouridine nucleosides 4a-c to the 6H-oxazolo[3,2-f]pyrimidine-5,7-dione derivatives 3a-c, we decided to further explore this reaction using previously unknown N3-substituted derivatives 4d-i (Scheme 2). 

Scheme 2. Reagents and conditions: (a) R2-X, K2CO3, DMF, 18 h, rt; b) TFA:H2O (8:2), rt 18 h;  (c) NaIO4, H2O, rt, 30-60 min; (d) NaBH4, H2O, rt, 1 h. (yields added, scheme corrected)

Consequently, isopropylidene-protected derivatives 6a-c were treated with alkyl or benzyl halides in DMF in the presence of anhydrous potassium carbonate resulting in formation of the appropriate alkyl derivatives 7a-f.15 Additionally, during the previously reported synthesis of 6a,11 we were also able to isolate a small amount of 5,3-dimethyl derivative 7f (18%). 6,5’-O-Anhydrouridine nucleosides 7a-f were deprotected under standard conditions using TFA:H2O (8:2) giving 4d-i derivatives. Deprotected nucleosides 4d-i were treated with sodium periodate followed by sodium borohydride which resulted in the formation of 6H-oxazolo[3,2-f]pyrimidine-5,7-diones 3d-i. We also investigated the possibility of modification of the target molecules side chains (Scheme 3). Thus, oxazolo[3,2-f]pyrimidine-5,7-dione 3a was treated with iodine and triphenylphosphine in THF resulting in the formation of derivative 3j with high yield. Compound 3j, bearing two iodide groups, could undergo further modifications via alkylation with amines, alcohols, phenols and thiols. Derivative 3a was also treated with DAST, which led to the fluorinated product 3k in low yield. The ORTEP drawings for representative compounds 3d and 3j with atomic labels are presented in Fig. 2. 















Fig. 2. ORTEP drawing showing 50% thermal ellipsoids of 3d (a) and 3j (b). Hydrogen atoms are shown as open circles.   






Fig. 3. Tracking of reaction progress by observation of position of anomeric H1’ proton signal in 4a

The synthesised 6H-oxazolo[3,2-f]pyrimidine-5,7-diones 3a-3k were tested in vitro to determine their cytotoxic activity against six cancer cell lines: U87 (glioma), MCF-7 (breast), HeLa (cervix), A549 (lung), A431 (vulvar), HCT-116 (colon) and also a non-cancer cell line, K-21 (fibroblasts). It has already been reported that structurally related pyrimido[1,6-c][1,3]oxazines exhibited moderate cytotoxic activity against breast and renal cancer cells in vitro.16,17 Additionally the anticancer drug – Camptothecin was used as a positive control. The obtained IC50 values are shown in Table 1. 

Table 1 Calculated IC50 values of 6H-oxazolo[3,2-f]pyrimidine-5,7-diones versus HeLa, HCT-116, U87, MCF-7, A431, A549 and K-21 cell lines in vitro.

cell line	K-21	HCT-116	U87	MCF-7	Hela	A431	A549
Compound number	IC50 values (mM)
3a	    >5	  3	    2.7	     1.07	    3.3	    >5	    3.6
3b 	   2.6	    2.1	    1.7	     1.75	    1.8	2.78	 2.25
3c	   3.5	    3.4	    2.5	   1.4	 3	     2.2	    4.5
3d	   3.7	    3.5	    3.2	      3.15	    3.3	     3.8	    3.6
3e	2	     1.55	    2.3	   1.4	    1.3	1.22	    1.6
3f	     0.56	   0.8	0.55	   0.4	    0.6	    0.6	    0.5
3g	    >5	   >5	    >5	   >5	    >5	    >5	    >5
3h	  3.1	     3	    2.8	  2.7	    3.2	2.75	    2.9
3i	   >5	   >5	    >5	   >5	    >5	       5	    >5
3j	  0.2	    0.15	     0.12	   0.23	    0.1	0.09	   0.4
3k	   >5	      3	    >5	   >5	2.75	    >5	    >5
Camptothecin	5.0x10-4	2.0x10-4	5.4x10-4	7.2x10-4	4.3x10-4	2.6x10-4	2.8x10-4





A series of novel, optically pure 6H-oxazolo[3,2-f]pyrimidine-5,7-diones 3a-3k were synthesized from 6,5’-O-anhydrouridine precursors through a novel rearrangement and contraction of the dioxazepine ring. The structures of the obtained compounds were confirmed by NMR spectra and single crystal X-ray structural analysis. The developed procedure enables the synthesis of a wide range of compounds with great structural diversity. The synthesized products are low molecular weight compounds with lead-like properties suitable for a medicinal chemistry optimization program. The cytotoxic effect of the synthesized compounds have been evaluated against several cell lines: U87, MCF-7, HeLa, A549, A431, HCT-116 and K-21. Although the synthesized compounds exhibited a rather weak cytotoxic effect on the investigated cell lines, the results and observed effects could help in the design of more active and selective inhibitors. Further structure optimization is now under investigation in our laboratory and will be reported elsewhere in due course.
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